'Cons of 'Brexit' for pharma would far outweigh pros'
This article was originally published in SRA
Executive Summary
Any benefits of the UK leaving the EU would be far outweighed by the disadvantages in the pharmaceutical and healthcare sector – not least the loss of participation in EU research projects and clinical trials – and could lead to a loss of jobs and a downturn in inward investment in the UK.